AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24412554
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg placebo once daily for four weeks
Trial: 24568073
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (635 mg EPA, 195 mg DHA)
Trial: 17227907
Drug: 37.5 mg
RxNorm normalized name: pemoline 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg of venlafaxine (low‐dose study)
Trial: 17227907
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of venlafaxine (high‐dose study)
Trial: 11593906
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment for localized disease (n=223)
Trial: 11593906
Drug: Primary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary treatment with radiotherapy (n=75) or radical prostatectomy (n=2) +/- hormonal treatment (n=77)
Trial: 30113350
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (bolus 0.2 mg/kg over 30 min followed by 0.12 mg/kg/h for 24 h)
Trial: 30113350
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (in opioid-naïve patients)
Trial: 17617382
Drug: Intranasal application
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal application of 24 IU oxytocin
Trial: 9820705
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III (AT III) treatment
Trial: 9502783
Drug: L-2-Oxothiazolidine-4-carboxylic acid
RxNorm normalized name: L-2-oxothiazolidine-4-carboxylic acid
DrugBank: Oxothiazolidinecarboxylic acid (DB12224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-2-Oxothiazolidine-4-carboxylic acid (OTC) 4.5 g
Trial: 6922470
Drug: Medication clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication clinic
Trial: 30894279
Drug: serlopitant, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: serlopitant, 5 mg, orally once daily for 8 weeks
Trial: 30894279
Drug: placebo, orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, orally once daily for 8 weeks
Trial: 27930386
Drug: GCSF 300
RxNorm normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCSF 300 μg twice daily for 5 days plus standard medical therapy (SMT)
Trial: 16460630
Drug: Alcohol gel
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [80% Alcohol Gel]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol gel
Trial: 11404722
Drug: OAC7 (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Clarithromycin 500 mg)
Trial: 11404722
Drug: OAM7 (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Metronidazole 500 mg)
Trial: 11404722
Drug: OTA7 (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTA7 (Omeprazole 20 mg b.i.d., Tetracycline 500 mg t.i.d., Amoxycillin 1 g b.i.d.)
Trial: 10421667
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b + placebo (monotherapy)
Trial: 10421667
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b + ribavirin (combination therapy)
Trial: 2750673
Drug: Warfarin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (2.5 mg/day, adjusted to lower VIIc to 70% of standard and increase prothrombin time INR to 1.6)
Trial: 2750673
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same dose sequence as warfarin)
Trial: 2750673
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (low-dose warfarin and low-dose aspirin 75 mg/day)
Trial: 835781
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) chemotherapy to the point of toxicity
Trial: 23232805
Drug: Oral doxifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral doxifluridine (800 mg/m2/day) in 3 divided doses
Trial: 23232805
Drug: Oral uracil/tegafur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral uracil/tegafur (UFT) (400 mg/m2/day) in 2 divided doses
Trial: 19671372
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone 50 micrograms in each nostril once daily for 3 months
Trial: 19671372
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray once daily for 3 months
Trial: 19671372
Drug: Topical mometasone
RxNorm normalized name: mometasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mometasone
Trial: 17057920
Drug: Amiodarone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (600 mg three times a day, started 30-56 hours before surgery)
Trial: 11225504
Drug: Individual and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual and group Cognitive Behavioral Therapy (CBT) and family anxiety management training
Trial: 11225504
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors, buspirone, and high‐potency benzodiazepines
Trial: 11225504
Drug: Psychotherapy, pharmacotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy, pharmacotherapy, and both
Trial: 9433396
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg CGP 51901
Trial: 9433396
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg CGP 51901
Trial: 9433396
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg CGP 51901
Trial: 31794072
Drug: SM-1 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-1 (a combination of diphenhydramine, zolpidem delayed release, and lorazepam delayed release)
Trial: 23127290
Drug: Maintenance cognitive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance cognitive behavior therapy (M-CBT)
Trial: 23127290
Drug: Residual symptoms
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual symptoms of agoraphobia at the end of acute-phase treatment
Trial: 22103994
Drug: Clinical findings
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical findings (oral thrush, hepatomegaly, lymphadenopathy, etc.)
Trial: 18925985
Drug: 2 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Hz rTMS treatment
Trial: 16968234
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg iron orally twice a day for 3 months
Trial: 11524329
Drug: small‐dose nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: small‐dose nalbuphine (0.2 microg/mL)
Trial: 11524329
Drug: large‐dose nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: large‐dose nalbuphine (0.4 microg/mL)
Trial: 11524329
Drug: atropine (1‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atropine (1‐mg bolus and 0.5 mg/h)
Trial: 9263382
Drug: Drug A
RxNorm normalized name: Drug additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug A (antidepressant immediate-release product)
Trial: 9263382
Drug: Drug B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug B (antiepileptic controlled release product)
Trial: 8348164
Drug: hCG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG therapy
Trial: 24275453
Drug: Inspiratory and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory and expiratory muscle training (Threshold Inspiratory Muscle Trainer and Threshold Positive Expiratory Pressure) for 15 minutes each, twice a day, five days/week for eight weeks
Trial: 15709984
Drug: Pre-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment with a proton pump inhibitor
Trial: 15709984
Drug: No pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-treatment with a proton pump inhibitor
Trial: 10509497
Drug: 10 parts
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 parts per million (ppm) inhaled nitric oxide
Trial: 10509497
Drug: Control ventilation
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control ventilation therapy without nitric oxide
Trial: 1942779
Drug: 1 liter
RxNorm normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 liter of 0.9% saline administered i.v. over one hour prior to amphotericin B
Trial: 1942779
Drug: 1 liter
RxNorm normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 liter of 5% dextrose in water administered i.v. over one hour prior to amphotericin B
Trial: 26639039
Drug: Aspirin reaction
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin reaction units >550
Trial: 19683936
Drug: Adenosine (ADO)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine (ADO) pretreatment (10‐min 100 microgkg(‐1)min(‐1) ADO) before application of the aortic cross‐clamp and antegrade 1 mmol l(‐1) adenosine high‐potassium ([K(+)]=20 mol l(‐1)) cold blood cardioplegia
Trial: 19683936
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) received antegrade cold (12 degrees C) high‐potassium ([K(+)]=20 mol l(‐1)) institute blood cardioplegia
Trial: 17257464
Drug: Cannabidiol/THC buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol/THC buccal spray
Trial: 15023508
Drug: Integrated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated group therapy (IGT)
Trial: 11464374
Drug: Bed rest
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bed rest (Group L)
Trial: 9581366
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health awareness campaign (test group)
Trial: 31371165
Drug: Symptom-based adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-based adjustment (SBA) with as-needed beclomethasone 80 μg and rescue short-acting β-agonist
Trial: 31371165
Drug: Provider-based guideline-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-based guideline-directed adjustment (PBA) with maintenance beclomethasone 80 μg/d (6-11 years) or 160 μg/d (12-17 years)
Trial: 29337780
Drug: Ascorbic acid-enriched
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid-enriched polyethylene glycol solution plus bisacodyl
Trial: 28094466
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy alone for CHD with β-blockers
Trial: 28094466
Drug: Early revascularization
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early revascularization for CHD with β-blockers
Trial: 23307544
Drug: Cognitive-enhancing drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-enhancing drugs
Trial: 21590281
Drug: Rimonabant (CB(1)
RxNorm normalized name: BroveX CB
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Rimonabant (CB(1) receptor antagonist) co-administered with ketamine
Trial: 18499880
Drug: Metoclopramide oral
RxNorm normalized name: metoclopramide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide oral solution 2 mg t.i.d.
Trial: 18499880
Drug: Metoclopramide tablets
RxNorm normalized name: Metoclopramide Tablets
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide tablets 5 mg t.i.d.
Trial: 9422301
Drug: Atracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 5%
Trial: 9422301
Drug: Atracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 25%
Trial: 9422301
Drug: Atracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 75%
Trial: 9422301
Drug: Atracurium 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 100%
Trial: 8272018
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg ASA
Trial: 8272018
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ASA
Trial: 3305002
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 g per day) for 2 weeks in trial 1
Trial: 3305002
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 g per day) for 4 weeks in trial 2
Trial: 28590364
Drug: Bitopertin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin (10 mg)
Trial: 23021323
Drug: Implant supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant supported dental restoration in patients with chronic periodontal diseases (Group A)
Trial: 10788945
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment for venous leg ulcers
Trial: 10788945
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment for pressure ulcers
Trial: 8829859
Drug: Ketorolac 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.75 mg.kg-1
Trial: 8829859
Drug: Ketorolac 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1.0 mg.kg-1
Trial: 8829859
Drug: Ketorolac 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1.5 mg.kg-1
Trial: 1340835
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus Metronidazole (TG)
Trial: 6367414
Drug: Bepridil (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepridil (400 mg once a day)
Trial: 30312434
Drug: CTC-positive status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC-positive status 2 years after chemotherapy
Trial: 30312434
Drug: CTC-negative status
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC-negative status 2 years after chemotherapy
Trial: 26895988
Drug: Gelatine tannate
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine tannate (250 mg, 4 times/day for children younger than 3 years; 500 mg, 4 times/day for children older than 3 years)
Trial: 20151053
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg based on an algorithm)
Trial: 11897771
Drug: ETRA (SB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETRA (SB 209670) - a dual endothelin type A/endothelin type B receptor antagonist
Trial: 10204835
Drug: Glucose (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (17.5 g)
Trial: 10204835
Drug: Aspartame (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (1 g)
Trial: 1981996
Drug: Oxatomide gel
RxNorm normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide gel at 5% applied twice a day for 14 days
Trial: 1981996
Drug: Follow-up without
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up without therapy for 14 days
Trial: 465619
Drug: Propranolol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.25 mg/kg body weight)
Trial: 24931228
Drug: Aspirin combined
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin combined with mechanical measures
Trial: 24931228
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) sodium and rivaroxaban sequentially combined with mechanical measures
Trial: 22104610
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg of inhaled budesonide twice per day
Trial: 12172328
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg / Indapamide 0.625 mg
Trial: 12172328
Drug: Perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 4 mg / Indapamide 1.25 mg
Trial: 7795086
Drug: Oral paste
RxNorm normalized name: Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paste and solution containing polymyxin, gentamicin, and nystatin
Trial: 7795086
Drug: Placebo paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo paste and solution
Trial: 2094065
Drug: Glucose-fructose-xylitol solution
RxNorm normalized name: fructose / glucose / phosphoric acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-fructose-xylitol solution (GFX-B) - 10.5% solution, infused continuously for 3 days postoperatively
Trial: 2094065
Drug: Sole glucose
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole glucose solution (PHY-3) - 10% glucose solution, infused continuously for 3 days postoperatively
Trial: 23909742
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (30 mg.kg(‐1) bolus followed by 10 mg.kg(‐1).h(‐1) continuous infusion)
Trial: 21896825
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine (MQ) 12.5 mg/kg/day for 2 days plus Artesunate (AS) 4.0 mg/kg/day for 3 days
Trial: 19839251
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg bid
Trial: 10624255
Drug: Homoeopathy treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathy treatment, details on dosage and duration not available
Trial: 8942578
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at a rate of 4 micrograms.kg‐1.min‐1
Trial: 1958393
Drug: Alizapride (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (16 mg/kg) alone
Trial: 1958393
Drug: Alizapride (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (16 mg/kg) + Dexamethasone (40 mg)
Trial: 1958393
Drug: Metoclopramide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (4 mg/kg) + Dexamethasone (40 mg)
Trial: 30104294
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 units/mL (IDeg‐100)
Trial: 27159857
Drug: Superpulsed low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superpulsed low level laser therapy (SLLLT) at T0, 24 hours, and 48 hours with a GaAs laser diode
Trial: 27159857
Drug: Control site
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control site (no SLLLT treatment)
Trial: 22894891
Drug: Yoga classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga classes (hatha yoga) held twice a week for 10 weeks
Trial: 12685875
Drug: Insulin monotherapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin monotherapy (n = 8)
Trial: 12685875
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus glibenclamide (n = 6)
Trial: 27306315
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBTuhr)
Trial: 15153167
Drug: Azathioprine continued
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine continued treatment